Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy in Treating Patients With Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed Ewing's family tumor as characterized by the following:~  * Positive MIC2 on immunohistochemistry OR~ * Evidence of a chromosomal translocation involving the EWS gene by conventional cytogenetics~    * t(11; 22) translocation or variant OR~   * Demonstration of EWS/FLI1 or EWS/ERG gene fusion by PCR or FISH~* Metastases outside the lung or pleura~* At least 1 measurable lesion outside of previously irradiated area~* No symptomatic or known CNS metastases~PATIENT CHARACTERISTICS:~Age:~* 15 to 65~Performance status:~* WHO 0-2~Life expectancy:~* Not specified~Hematopoietic:~* WBC at least 3,000/mm3~* Neutrophil count at least 2,000/mm3~* Platelet count at least 100,000/mm3~Hepatic:~* Bilirubin less than 3 mg/dL~* Albumin greater than 2.5 g/dL~Renal:~* Creatinine less than 1.2 mg/dL~* Creatinine clearance greater than 70 mL/min~Cardiovascular:~* No history of uncontrolled cardiovascular disease~Other:~* No other severe medical illness, including psychosis~* No other prior primary malignancy except adequately treated carcinoma in situ of the cervix or basal cell skin cancer~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No prior chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* See Disease Characteristics~Surgery:~* Not specified

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).